Nina Žigart

Nina Žigart

Auto-generated profile, based on publicly available information

Nina Žigart

Sandoz Technical Operations, MS&T Antiinfectives, Mengeš, Slovenia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2019 in Organic Process Research & Development
Verified
Journal Article
Open access
TTTim Tome
Tim Tome
NŽNina Žigart
Nina Žigart
ZCZdenko Casar
Zdenko Casar
AOAleš Obreza
Aleš Obreza
This review presents the Analytical Quality by Design (AQbD) concept, an extension of Quality by Design (QbD), which was introduced in 2004 by the U.S. Food and Drug Administration (FDA) and approved in 2005 by the International Conference on Harmonisation (ICH). AQbD is a systematic approach to method development, controlling all stages of the analytical procedure life cycle. It includes a definition of the analytical target profile (ATP), identification of critical method parameters or factors, and selection of critical method attributes (CMAs) or responses. Screening and response-surface experimental designs allow the recognition of significant factors and their optimization by statistical analysis. The factor–response relationship is described by a mathematical model, which is able to predict the optimal response. Multivariate combinations of factors fulfilling the CMA requirements are presented in the design space or method operable design region (MODR), where robust method performance is ensured. This review presents the theoretical background of AQbD for method development and its workflow through recently published cases in which the AQbD concept proved to be a reliable and effective approach. Analytical methods developed by using the AQbD approach are highly robust, are easily validated, have shorter run times, and are capable of determining a higher number of analytes in one run compared with the methods developed by the one-factor-at-a-time (OFAT) approach.

7 June 2019 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
NŽNina Žigart
Nina Žigart
ZCZdenko Casar
Zdenko Casar
Introduction: Studies presented in patents show that a novel chemotherapeutic agent, venetoclax, might be useful in additional therapeutic indications. Venetoclax is approved in America for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venetoclax selectively inhibits the B-cell lymphoma-2 (Bcl-2) protein, an anti-apoptotic protein that can be overexpressed in most B-cell lymphoid malignancies. Areas covered: This is a review of all the patents granted until November 2018, with venetoclax in the examples or claim section of the patent document. The patents include the synthesis, polymorphism, formulations, in vitro and in vivo efficacy as well as the therapeutic application of venetoclax. Expert opinion: The approved indications for treatment with venetoclax are limited but expanding rapidly. Studies suggest that venetoclax might be useful in several other therapeutic indications, mostly other hematological malignancies. Numerous studies use venetoclax in combinations with other therapeutic agents. Such combinational treatment shows promising results in additional indications as well as drug resistant cancers. Venetoclax is an interesting new therapeutic involved in a variety of clinical research. Patent applications in recent years even include venetoclax in somewhat exotic fields such as type 1 diabetes, asthma and Zika virus treatment.

28 November 2025 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
NŽNina Žigart
Nina Žigart
PLPetra Pivk Lukančič
Petra Pivk Lukančič
TDTjaša Drčar
Tjaša Drčar
JPJan Peterka
Jan Peterka
MPMaja Harej Perko
Maja Harej Perko
PMPeter Mrak
Peter Mrak
Despite the ability of mega synthases to construct complex structures with high precision, the main product is often accompanied by minor congeners because of relaxed selectivity of biosynthetic steps. In the case of polyketides, these may arise from promiscuity of acyltransferase domains while selecting the extender building blocks. This yields compounds which can differ only slightly from the main product and are therefore notoriously difficult to separate. For compounds in medicinal use, such congeners are considered impurities and must be precisely quantified in commercial production through use of reference standards. The immunosuppressants FK506, FK520, and its chlorinated derivate pimecrolimus, are well known for accumulation of minor congeners in the fermentation, which demands costly and lengthy purification with industrial HPLC to obtain material of sufficient purity. The relaxed selectivity of the AT domain in module 4 of FK506/520 PKS results in production of FK506, FK506D, FK520, and FK523 from the same system. Here, we investigate additional minor impurities, specifically the 11-, 17-, and 19-ethyl FK520 derivatives. Because the PKS can process these analogues to completion, it is reasonable to expect that strategic replacement of AT domains in modules 9, 6, and 5 (respectively), would enhance their production. Indeed, we show a direct, exclusive and high titer biosynthesis of these analogues through PKS engineering, replacing tedious and costly isolation by preparative HPLC and significantly improving access to these minor congeners. In addition, by using the AT4 as the donor domain, an interesting system is obtained, containing identical promiscuous AT domains at two different positions, and consequently distinct intra- and intermodular context. Media-dependent extender pool modulation toward methylmalonyl-CoA showed unexpected but consistent distribution of the four predicted analogues for each of the engineered systems. Despite the use of identical ATs, extender incorporation preference is different, depending on the modular context. It appears that the selectivity of the downstream AT4-containing module depends on the structural features of the incoming acyl chain; features installed by a module well upstream in the assembly line. Therefore, the global context of the PKS may be more impactful to the outcome of AT-engineering experiments than is generally considered. Graphical abstract